Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase III FORWARD I Study in Ovarian Cancer

    September 2022 in “ Annals of Oncology ”
    K.N. Moore, A.M. Oza, N. Colombo, A. Oaknin, Giovanni Scambia, D. Lorusso, Susana Banerjee, C. Murphy, J. Konner, P. Lim, M. Prasad-Hayes, B.J. Monk, J. Wang, M.J. Birrer, I.B. Vergote
    TLDR Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
    The phase III FORWARD I trial compared mirvetuximab soravtansine (MIRV) to standard chemotherapy (CTX) in patients with platinum-resistant ovarian cancer, focusing on patient-reported outcomes (PROs). MIRV showed significant improvements in gastrointestinal symptoms, physical functioning, and various quality of life measures, including chemotherapy side effects, sexuality, hair loss, pain severity, and body image. The likelihood of gastrointestinal symptom deterioration was significantly lower with MIRV. Similar trends were observed in the FRα-high population, although not all results were statistically significant. These findings support the use of MIRV over CTX and will be further investigated in the ongoing MIRASOL trial.
    Discuss this study in the Community →